PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
35.955
-0.405 (-1.11%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close36.360
Open36.130
Bid35.920 x 900
Ask35.930 x 1000
Day's Range35.730 - 36.220
52 Week Range32.320 - 39.430
Volume8,160,250
Avg. Volume21,231,053
Market Cap210.321B
Beta0.93
PE Ratio (TTM)9.99
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.74%)
Ex-Dividend Date2018-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investing Insights: Conference Highlights and Mind the Gap
    Morningstar2 days ago

    Investing Insights: Conference Highlights and Mind the Gap

    Discussions with Mellody Hobson and Jeremy Grantham; Pfizer; and oil prices on this week's edition.

  • Strong Drug Pipeline Bolsters Undervalued Pfizer
    Morningstar5 days ago

    Strong Drug Pipeline Bolsters Undervalued Pfizer

    The wide-moat firm is going through a paradigm shift, but it is well-positioned for growth.

  • Reuters5 hours ago

    FOCUS-How U.S. tax reform rewards companies that shift profit to tax havens

    The corporate tax cut passed by U.S. President Donald Trump and fellow Republicans that was in part designed to help dissuade U.S. companies from moving profits overseas may instead make the practice a lot more rewarding. The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. is a case in point.

  • Investopedia6 hours ago

    5 Drug Stocks With Fat Payouts

    Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.

  • Better Buy: Pfizer Inc. vs. Johnson & Johnson
    Motley Foolyesterday

    Better Buy: Pfizer Inc. vs. Johnson & Johnson

    How do these two big pharma stocks compare in a head-to-head match?

  • 25 Blue-Chip Stocks That Mutual Fund Managers Love Most
    Kiplinger3 days ago

    25 Blue-Chip Stocks That Mutual Fund Managers Love Most

    Investors continue to pour money into passive vehicles such as indexed mutual funds and exchange-traded funds. However, good old-fashioned stock picking and asset allocation with a human touch still rules in some areas - including in the well-trodden world of blue-chip stocks. After all, actively managed mutual funds run by professional portfolio managers still dwarf their passive cousins. At the end of 2017, actively managed funds had a total of $11.4 trillion in assets under management, according to Morningstar. Passive funds and ETFs controlled $6.7 trillion in assets. As we've noted before, the "smart money" doesn't always live up to the high fees and hype, but it's worth keeping tabs on what they're doing nonetheless. That's even more true for actively managed mutual funds. After all, they comprise a much larger swath of institutional investor dollars. Using data from Morningstar Direct, we were able to discover which blue-chip stocks are most widely held by the biggest actively managed U.S. mutual funds. In other words, these are the 25 most popular stock picks among professional portfolio managers. Not every one of the following stocks is necessarily a buy at current levels, but it's fair to say that they are all superstar companies. And the most popular pick of all probably will surprise you. SEE ALSO: 53 Best Dividend Stocks for 2018 and Beyond

  • Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
    Motley Fool3 days ago

    Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

    These two small biotechs with promising NASH drugs could attract several big suitors.

  • InvestorPlace3 days ago

    Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

    Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.

  • MarketWatch4 days ago

    ViiV Healthcare reports positive results for late-stage HIV trials

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.

  • Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
    Zacks5 days ago

    Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer

    Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.

  • Forbes5 days ago

    This Rare 10.5% Dividend Won't Be Cheap For Long

    Let’s be honest: with an income stream like that, backed by household names like Pfizer and AT&T—more on these two stocks below—you’d leap at the chance, right? Funny thing is, for a brief, shining moment in the not-so-distant past (early March 2009), many blue chips actually did deliver payouts of 7%, 10% and more. You needed nerves of steel to plunge in while everyone else was sprinting from the worst market crash since 1929.

  • Should You Buy Pfizer Inc (NYSE:PFE) For Its Dividend?
    Simply Wall St.6 days ago

    Should You Buy Pfizer Inc (NYSE:PFE) For Its Dividend?

    Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Pfizer Inc (NYSE:PFE) has returned to shareholders over the pastRead More...

  • Can This Pharma's $14 Billion Bet Succeed?
    Motley Fool6 days ago

    Can This Pharma's $14 Billion Bet Succeed?

    A big component of Pfizer's Medivation purchase could get a chance to prove itself soon.

  • 3 Stocks to Supplement Your Social Security Income
    Motley Fool6 days ago

    3 Stocks to Supplement Your Social Security Income

    These stocks have what it takes to help meet your financial needs in retirement beyond what Social Security can provide.

  • The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty

    The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty

  • Forbes7 days ago

    A Story Of Devastation And Rebirth: The Former Pfizer Research Labs In Ann Arbor

    December 4, 2006 proved to be a fateful day for Pfizer–the day when it announced that the highly touted cholesterol modifying drug, torcetrapib, was being dropped from development. This drug had potent cholesterol modifying properties: doubling a heart patient’s HDL-c while simultaneously lowering LDL-c by 20% (on top of Lipitor’s 40% LDL-c lowering effect). When patients took torcetrapib in combination with Lipitor, their lipoprotein levels essentially normalized, results that were unprecedented.

  • 3 Dividend Stocks Ideal for Retirees
    Motley Fool10 days ago

    3 Dividend Stocks Ideal for Retirees

    Whether it's a steady source of income, capital appreciation to grow your nest egg, or both, these three dividend stocks look like smart choices.

  • The FDA and EMA on Pfizer’s Talazoparib
    Market Realist10 days ago

    The FDA and EMA on Pfizer’s Talazoparib

    On June 7, Pfizer (PFE) announced that the FDA and the European Medicines Agency (or EMA) provided updates on the regulatory submissions of Talazoparib for the treatment of locally advanced or metastatic breast cancer. In this article, we’ll examine the drug, regulatory submissions, and clinical trials related to the drug.

  • Barrons.com10 days ago

    Lilly, Pfizer: Both Unloved but Ready to Grow

    Shares of Lilly (LLY) and Pfizer (PFE) have eked out small year-to-date gains, but the stocks are higher Friday, thanks to bullish notes from Cantor Fitzgerald. Analyst Louise Chen initiated coverage of both stocks at Overweight, with a $100 price target for Lilly and $45 price target for Pfizer. For Lilly, she highlights the growth prospects for the company's main drugs, Trulicity, Jardiance, Taltz and Verzenio, and she's also enthusiastic about its pipeline assets, which she believes are underappreciated, especially in the pain category.

  • Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
    Zacks10 days ago

    Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

    Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

  • Top Stock Reports for Pfizer, Union Pacific & Broadcom
    Zacks10 days ago

    Top Stock Reports for Pfizer, Union Pacific & Broadcom

    Top Stock Reports for Pfizer, Union Pacific & Broadcom

  • Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
    Zacks10 days ago

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

  • In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection
    American City Business Journals11 days ago

    In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection

    The company is pushing into clinical trials for its experimental broad-spectrum vaccine against a bacterium that causes pneumonia and bloodstream infections.

  • Pfizer Presents the Final Data on Dacomitinib
    Market Realist11 days ago

    Pfizer Presents the Final Data on Dacomitinib

    Pfizer (PFE) presented its final data on dacomitinib at the 54th Annual Meeting of the American Society of Clinical Oncology (or ASCO) on June 4.

  • Pfizer’s Highlights from the 54th Annual Meeting of ASCO
    Market Realist11 days ago

    Pfizer’s Highlights from the 54th Annual Meeting of ASCO

    The 54th Annual Meeting of the American Society of Clinical Oncology (or ASCO) was held in Chicago from June 1 to June 5.